Custom CAR-T Cell Development
CAR-T cell therapy is a revolutionary cancer treatment that involves genetically engineering immune cells, using either the patient’s own cells or allogeneic cells, to recognize and attack cancer cells using a Chimeric Antigen Receptor (CAR). This therapy has shown remarkable success in treating some types of blood cancers, such as leukemia and lymphoma, even in patients who have not responded to other treatments. While CAR-...
CAR T-Cell Therapy
Overview
CAR-T is a cross of immunotherapy, gene therapy, and cellular therapy. Many successful immunotherapies are based on checkpoint inhibitors that block the mechanisms tumor cells use to hide from T cells. CAR-T immunotherapies go one step further by engineering T cells to enhance the immune response against a specific tumor antigen. CAR-T is a promising approach for cancer and other diseases, especially severe cancers that do not respond well to othe...
CAR-T Cell Therapy
Engineering T cells using a chimeric antigen receptor (CAR) to boost specific immune cell killing has made significant progress in the treatment of some cancer types. CAR-T cell therapy may also have potential benefits beyond cancer treatment, including treatments for infectious and chronic inflammatory diseases such as hepatitis, HIV/AIDS, lupus, and arthritis. Companies are also investigating CAR-T cell therapy in organ transplantation to eliminate the n...
CAR-T Cell Therapy
Engineering T cells using a chimeric antigen receptor (CAR) to boost specific immune cell killing has made significant progress in the treatment of some cancer types. CAR-T cell therapy may also have potential benefits beyond cancer treatment, including treatments for infectious and chronic inflammatory diseases such as hepatitis, HIV/AIDS, lupus, and arthritis. Companies are also investigating CAR-T cell therapy in organ transplantation to eliminate the n...
Siglecs & Immunotherapy
BPS has released a number of Siglec proteins and stable cell lines for studying immune-oncology and immune regulation .
Cells of the immune system express a multitude of complex glycans on their surfaces, making them highly recognizable by diverse glycan-binding proteins. Siglecs (Sialic-acid-binding immunoglobulin-like lectins) are type I transmembrane proteins that bind to glycans containing sialic acid. These highly polymorphic proteins have very dist...
